Phase III trial of canakinumab in Covid-19 fails to meet primary endpoint

An interim analysis from the Phase III CAN-COVID trial (n=454) found canakinumab did not improve survival without the need for mechanical ventilation up to day 29 (88.8% vs 85.7% placebo) in patients with cytokine release syndrome as a consequence of pneumonia.

Source:

BioWorld